| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -4,944 | -1,801 |
| Purchase of short-term investments | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Payment of stock issuance costs | 327 | 327 |
| Net cash used in financing activities | -327 | -327 |
| Net decrease in cash and cash equivalents | -5,271 | -2,128 |
| Cash and cash equivalents at beginning of period | 22,133 | - |
| Cash and cash equivalents at end of period | 16,862 | - |
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)